Liberum Capital reissued their hold rating on shares of Shire (LON:SHP) in a research report report published on Wednesday. The firm currently has a GBX 4,000 ($55.26) price target on the biopharmaceutical company’s stock.

Other analysts also recently issued research reports about the stock. Barclays assumed coverage on shares of Shire in a report on Thursday, February 1st. They set an equal weight rating for the company. Credit Suisse Group decreased their price objective on shares of Shire from GBX 4,500 ($62.17) to GBX 4,000 ($55.26) and set an outperform rating for the company in a report on Thursday, February 15th. Kepler Capital Markets restated a buy rating and set a GBX 4,600 ($63.55) price objective on shares of Shire in a report on Thursday, February 15th. Shore Capital restated a buy rating on shares of Shire in a report on Friday, February 23rd. Finally, Citigroup restated a buy rating and set a GBX 5,500 ($75.99) price objective on shares of Shire in a report on Friday, December 8th. Five equities research analysts have rated the stock with a hold rating, twelve have issued a buy rating and one has given a strong buy rating to the company. The stock presently has a consensus rating of Buy and a consensus target price of GBX 4,955.88 ($68.47).

Shares of Shire (SHP) opened at GBX 3,192.50 ($44.11) on Wednesday. Shire has a 1-year low of GBX 2,940.50 ($40.63) and a 1-year high of GBX 5,021 ($69.37). The stock has a market cap of $29,080.00 and a PE ratio of 2,186.64.

The firm also recently announced a dividend, which will be paid on Tuesday, April 24th. Shareholders of record on Thursday, March 8th will be given a dividend of GBX 21.46 ($0.30) per share. This represents a yield of 0.67%. The ex-dividend date of this dividend is Thursday, March 8th. This is a positive change from Shire’s previous dividend of $3.85.

In other Shire news, insider Dominic Blakemore bought 165 shares of the business’s stock in a transaction on Tuesday, December 19th. The stock was purchased at an average price of GBX 3,790 ($52.36) per share, for a total transaction of £6,253.50 ($8,639.82).

ILLEGAL ACTIVITY WARNING: “Liberum Capital Reiterates Hold Rating for Shire (SHP)” was reported by The Cerbat Gem and is the property of of The Cerbat Gem. If you are reading this news story on another website, it was copied illegally and republished in violation of U.S. and international copyright law. The original version of this news story can be accessed at

Shire Company Profile

Shire plc is a biotech company focused on serving people with rare diseases and other specialized conditions. The Company’s segment is engaged in research, development, licensing, manufacturing, marketing, distribution and sale of specialist medicines. It focuses its development resources on projects in various therapeutic areas (TAs), including Neuroscience, Ophthalmology, Hematology, Oncology, Immunology, Gastrointestinal (GI)/Metabolic/Endocrinology Diseases.

Analyst Recommendations for Shire (LON:SHP)

Receive News & Ratings for Shire Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Shire and related companies with's FREE daily email newsletter.